Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Lack of Evidence for the Efficacy of Memantine in Mild Alzheimer Disease

Lack of Evidence for the Efficacy of Memantine in Mild Alzheimer Disease CLINICAL TRIALS SECTION EDITOR: IRA SHOULSON, MD ONLINE FIRST Lack of Evidence for the Efficacy of Memantine in Mild Alzheimer Disease Lon S. Schneider, MD, MS; Karen S. Dagerman, MS; Julian P. T. Higgins, PhD; Rupert McShane, MD Objective: We directly assessed the clinical trials’ evi- MMSE scores of 10-19). There were no significant dif- dence for memantine’s efficacy in mild Alzheimer dis- ferences between memantine and placebo on any out- ease (AD). Memantine is indicated in the United States come for patients with mild AD, either within any trial and Europe for moderate to severe AD, which is diag- or when data were combined: mean differences (95% con- nosed if a patient has a Mini-Mental State Examination fidence intervals [CIs]) on the Alzheimer Disease As- (MMSE) score of less than 15 or less than 20, respec- sessment Scale–cognitive subscale (ADAS-cog), the Cli- tively. Yet memantine is very frequently prescribed for nician’s Interview-Based Impression of Change plus caregiver’s input (CIBIC-plus), the Alzheimer Disease Co- mild AD and mild cognitive impairment, and a manu- operative Study–activities of daily living (ADCS-ADL) facturer-sponsored meta-analysis claimed its efficacy in scale, and the Neuropsychiatric Inventory (NPI) were mild AD. −0.17 (95% CI, −1.60 to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Neurology American Medical Association

Lack of Evidence for the Efficacy of Memantine in Mild Alzheimer Disease

Download PDF
8 pages

Loading next page...
 
/lp/american-medical-association/lack-of-evidence-for-the-efficacy-of-memantine-in-mild-alzheimer-2nNfCPZFhv

References (65)

Publisher
American Medical Association
Copyright
Copyright 2011 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6149
eISSN
2168-6157
DOI
10.1001/archneurol.2011.69
pmid
21482915
Publisher site
See Article on Publisher Site

Abstract

CLINICAL TRIALS SECTION EDITOR: IRA SHOULSON, MD ONLINE FIRST Lack of Evidence for the Efficacy of Memantine in Mild Alzheimer Disease Lon S. Schneider, MD, MS; Karen S. Dagerman, MS; Julian P. T. Higgins, PhD; Rupert McShane, MD Objective: We directly assessed the clinical trials’ evi- MMSE scores of 10-19). There were no significant dif- dence for memantine’s efficacy in mild Alzheimer dis- ferences between memantine and placebo on any out- ease (AD). Memantine is indicated in the United States come for patients with mild AD, either within any trial and Europe for moderate to severe AD, which is diag- or when data were combined: mean differences (95% con- nosed if a patient has a Mini-Mental State Examination fidence intervals [CIs]) on the Alzheimer Disease As- (MMSE) score of less than 15 or less than 20, respec- sessment Scale–cognitive subscale (ADAS-cog), the Cli- tively. Yet memantine is very frequently prescribed for nician’s Interview-Based Impression of Change plus caregiver’s input (CIBIC-plus), the Alzheimer Disease Co- mild AD and mild cognitive impairment, and a manu- operative Study–activities of daily living (ADCS-ADL) facturer-sponsored meta-analysis claimed its efficacy in scale, and the Neuropsychiatric Inventory (NPI) were mild AD. −0.17 (95% CI, −1.60 to

Journal

JAMA Neurology – American Medical Association

Published: Aug 1, 2011

There are no references for this article.